Is Mounjaro a GLP-1? Yes — and Also Something More (Tirzepatide Explained)
Mounjaro (tirzepatide) is a GLP-1 receptor agonist — and a GIP receptor agonist. The dual mechanism, the approved uses, the trial results, and how Mounjaro differs from Ozempic and Zepbound.
The short answer is yes — Mounjaro is a GLP-1 receptor agonist. But it's also a GIP receptor agonist, which means it does something Ozempic and Wegovy can't: activate two metabolic hormone pathways simultaneously. That second mechanism is why tirzepatide (Mounjaro's active ingredient) outperforms single-receptor GLP-1s on average weight loss in trials.
Mounjaro's mechanism is worth understanding — along with what it's approved for, and how it stacks up against the other major weight-loss and diabetes drugs.
What Mounjaro is
| Aspect | Detail |
|---|---|
| Brand name | Mounjaro |
| Active ingredient | Tirzepatide |
| Drug class | Dual GLP-1 / GIP receptor agonist |
| Maker | Eli Lilly |
| FDA approval | 2022 |
| Approved use | Type 2 diabetes |
| Form | Weekly subcutaneous injection |
| Dose range | 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg |
Mounjaro is FDA-approved for type 2 diabetes specifically. For weight management, the same molecule is sold under the brand name Zepbound (also Eli Lilly). Many clinicians prescribe Mounjaro off-label for weight loss in patients without T2D, but the weight-management approval belongs to Zepbound.
The "GLP-1 + GIP" dual mechanism
Tirzepatide binds two receptors:
- GLP-1 receptor — same as Ozempic, Wegovy and other single- agonist drugs. This produces appetite suppression, slowed gastric emptying, glucose-dependent insulin release.
- GIP receptor — Glucose-dependent Insulinotropic Polypeptide, another incretin hormone. GIP receptor activation amplifies the insulin response and appears to have additional effects on fat metabolism via adipose tissue.
Mounjaro is the first FDA-approved drug to activate both. The combined effect is meaningfully greater than activating either alone.
For deeper mechanism context, see GLP-1 receptor agonists.
How effective is Mounjaro vs other GLP-1s
In head-to-head trials and equivalent dose comparisons:
| Drug | Class | Avg weight loss (top dose, weight-mgmt trial) |
|---|---|---|
| Zepbound 15 mg (same drug as Mounjaro) | Dual GLP-1/GIP | ~21% body weight |
| Wegovy 2.4 mg | Single GLP-1 | ~15% body weight |
| Saxenda 3.0 mg | Single GLP-1 | ~8% body weight |
In the SURPASS trial program (T2D), Mounjaro produced superior A1c reduction vs semaglutide. In SURMOUNT-1 (weight management with tirzepatide / Zepbound), 21% average weight loss vs ~15% for semaglutide/Wegovy in STEP-1.
Mounjaro vs Zepbound (same drug, different label)
Both are tirzepatide. The differences:
| Mounjaro | Zepbound | |
|---|---|---|
| FDA-approved for | Type 2 diabetes | Chronic weight management; OSA |
| Insurance coverage | Strong for T2D | Variable for weight loss |
| Off-label use | Common for weight loss without T2D | Off-label for T2D less common |
| Cash price | ~$1,069/month | ~$1,299/month (pens); LillyDirect vials $349-$499 |
| Dose pens | Pens at 2.5-15 mg | Pens, KwikPen, LillyDirect vials |
The drug is the same. The label, the price, and the insurance coverage all differ.
How Mounjaro is dosed
Slow titration is the standard for tolerability:
| Week | Dose |
|---|---|
| 1-4 | 2.5 mg/week |
| 5-8 | 5 mg/week |
| 9-12 | 7.5 mg/week |
| 13-16 | 10 mg/week |
| 17-20 | 12.5 mg/week |
| 21+ | 15 mg/week (max) |
Most patients maintain at 5, 10, or 15 mg depending on response and tolerability.
Storage: refrigerate single-dose pens (36-46°F); they can be at room temperature up to 86°F for 21 days. KwikPen and multi-dose vials have similar guidelines.
Side effects
Same general profile as other GLP-1s:
- Common: Nausea, diarrhea, vomiting, constipation, decreased appetite, stomach pain, indigestion
- Less common: Reflux, fatigue, injection-site reactions, hair thinning
- Rare: Pancreatitis, gallbladder issues, severe hypoglycemia (in patients on insulin or sulfonylureas), thyroid C-cell tumors (boxed warning, rodent data), severe allergic reactions
Full breakdown: GLP-1 side effects.
Mounjaro vs Ozempic (the most-asked comparison)
| Mounjaro | Ozempic | |
|---|---|---|
| Class | Dual GLP-1/GIP | Single GLP-1 |
| Active ingredient | Tirzepatide | Semaglutide |
| Approved for | Type 2 diabetes | Type 2 diabetes |
| Maker | Eli Lilly | Novo Nordisk |
| Dose range | 2.5-15 mg/week | 0.25-2.0 mg/week |
| A1c reduction | Higher | Strong |
| Weight loss in T2D trials | Higher | Moderate |
| Cardiovascular benefit | Suggestive (data still maturing) | Established (SELECT, others) |
For weight loss outside of T2D, the relevant comparison is Zepbound vs Wegovy, not Mounjaro vs Ozempic. See best GLP-1 for weight loss.
Cost
- Cash pay (pens): ~$1,069/month
- With Eli Lilly Mounjaro Savings Card + commercial insurance: as low as $25/month
- Mounjaro is not directly sold via LillyDirect — that program is for Zepbound
If you're being treated for T2D and your insurance covers Mounjaro, the savings card brings costs to a manageable copay for most patients.
Pros and cons summary
Pros:
- Most effective GLP-1-class drug currently approved (via the GIP arm)
- Strong A1c reduction for T2D
- Weekly dosing
- FDA-approved with substantial trial evidence
- Increasing insurance coverage
Cons:
- Cash price among the highest in class
- Dose-related side effects (nausea most prominent)
- Boxed warning for thyroid C-cell tumors (rodent data)
- Generic / biosimilar not expected for years
- Weight regain expected after discontinuation
Who shouldn't take Mounjaro
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- Personal history of pancreatitis
- Severe gastroparesis
- Pregnancy or planning pregnancy
- Active or recent eating disorder
- Type 1 diabetes (different mechanism; not appropriate)
FAQ
Is Mounjaro a GLP-1? Yes — Mounjaro is a GLP-1 receptor agonist. It's also a GIP receptor agonist, making it a dual-action drug.
Is Mounjaro better than Ozempic? In trials for T2D, Mounjaro produced greater A1c reduction and weight loss than semaglutide (Ozempic). It's also more expensive.
Is Mounjaro the same as Zepbound? Same active ingredient (tirzepatide), different brand labels and indications. Mounjaro for diabetes; Zepbound for weight management and OSA.
Can Mounjaro be used for weight loss? Often prescribed off-label for weight loss in patients without T2D. For on-label weight-loss use, the prescription should be Zepbound.
What's the difference between tirzepatide and semaglutide? Tirzepatide is a dual GLP-1/GIP agonist; semaglutide is a single GLP-1 agonist. Tirzepatide produces greater weight loss on average.
This article is for educational purposes only and is not medical advice. Discuss medication choices with a qualified healthcare professional.